The histone deacetylase inhibitor romidepsin is a potential therapeutic for metastatic osteosarcoma

被引：0
|
作者：
Seiden, Emily E.
Richardson, Spencer M.
Ramnath, Shrey
Whiteside, Tia
Coy, Kathryn L.
Sinn, Anthony L.
Capitano, Maegan L.
Pollok, Karen E.
Collier, Chris D.
Greenfield, Ed M.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-7554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7554
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Repurposing Romidepsin, a Structurally- and Functionally-Unique Histone Deacetylase Inhibitor (HDACi), for Metastatic Osteosarcoma
    Seiden, Emily
    Richardson, Spencer
    Ramnath, Shrey
    Whiteside, Venetia
    Coy, Kathryn
    Sinn, Anthony
    Capitano, Maegan
    Pollok, Karen
    Collier, Christopher
    Greenfield, Edward M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 : 85 - 85
  • [2] The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
    Conforti, Franco
    Davies, Elizabeth R.
    Calderwood, Claire J.
    Thatcher, Thomas H.
    Jones, Mark G.
    Smart, David E.
    Mahajan, Sumeet
    Alzetani, Aiman
    Havelock, Tom
    Maher, Toby M.
    Molyneaux, Philip L.
    Thorley, Andrew J.
    Tetley, Teresa D.
    Warner, Jane A.
    Packham, Graham
    Ganesan, A.
    Skipp, Paul J.
    Marshall, Benjamin J.
    Richeldi, Luca
    Sime, Patricia J.
    O'Reilly, Katherine M. A.
    Davies, Donna E.
    ONCOTARGET, 2017, 8 (30) : 48737 - 48754
  • [3] Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin
    Newbold, Andrea
    Lindemann, Ralph K.
    Cluse, Leonie A.
    Whitecross, Kate F.
    Dear, Anthony E.
    Johnstone, Ricky W.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (05) : 1066 - 1079
  • [4] Clinical development of histone deacetylase inhibitor romidepsin
    Guan, Peng
    Fang, Hao
    DRUG DISCOVERIES AND THERAPEUTICS, 2010, 4 (06): : 388 - 391
  • [5] Romidepsin: a novel histone deacetylase inhibitor for cancer
    Bertino, Erin M.
    Otterson, Gregory A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (08) : 1151 - 1158
  • [6] Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin
    Cabell, C.
    Bates, S.
    Piekarz, R.
    Whittaker, S.
    Kim, Y.
    Godfrey, C.
    Schoonmaker, C.
    McCulloch, W.
    Nichols, J.
    Burris, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies
    Jain, Nitin
    Odenike, Olatoyosi
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (18) : 3073 - 3084
  • [8] Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer
    Haigentz, Missak, Jr.
    Kim, Mimi
    Sarta, Catherine
    Lin, Juan
    Keresztes, Roger S.
    Culliney, Bruce
    Gaba, Anu G.
    Smith, Richard V.
    Shapiro, Geoffrey I.
    Chirieac, Lucian R.
    Mariadason, John M.
    Belbin, Thomas J.
    Greally, John M.
    Wright, John J.
    Haddad, Robert I.
    ORAL ONCOLOGY, 2012, 48 (12) : 1281 - 1288
  • [9] Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin.
    Cabell, Christopher
    Bates, Susan
    Piekarz, Richard
    Whittaker, Sean
    Kim, Youn H.
    Currie, Michelle
    Godfrey, C. J.
    Schoonmaker, Christopher
    Nichols, Jean
    Nix, Darrell
    Burris, Howard A.
    BLOOD, 2009, 114 (22) : 1428 - 1429
  • [10] Use of class I histone deacetylase inhibitor romidepsin in combination regimens
    Petrich, Adam
    Nabhan, Chadi
    LEUKEMIA & LYMPHOMA, 2016, 57 (08) : 1755 - 1765
12345